中国基金报·2026-01-27 14:39Group 1 - The Nipah virus outbreak in India has raised attention, particularly in the stock market, with related concept stocks experiencing significant gains. Companies like Capbio and Da'an Gene have seen consecutive price increases [2] - The Nipah virus primarily spreads through direct contact with infected animals, patients, and contaminated materials, with a low survival rate in the environment. The outbreak is mainly concentrated in West Bengal, India, which does not border China, minimizing the impact on China [2] - Early detection of the Nipah virus is crucial for clinical intervention and public health measures, as the incubation period ranges from 3 to 14 days, and initial symptoms resemble those of influenza [2] Group 2 - Several A-share listed companies have disclosed their technology and product layouts related to Nipah virus testing. For instance, Wanfu Bio has launched various forms of Nipah virus nucleic acid test kits compatible with their molecular POCT platform [4] - Shengxiang Bio has actively engaged with local health authorities in India to address the outbreak, developing corresponding detection solutions based on their fluorescence PCR technology [4] - Capbio has developed a nucleic acid test kit for the Nipah virus, providing essential technical support for global quarantine and disease control monitoring [6] Group 3 - Some A-share companies have clarified their positions regarding the Nipah virus, stating they do not have relevant business layouts. For example, Hualan Biological announced that it primarily manufactures human vaccines and does not have products for Nipah virus prevention [7] - Other companies like Yirui Bio, Renhe Pharmaceutical, and CanSino have also confirmed through investor interactions that they do not have related products [7]